X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to advance the R&D of Assembly Bio’s portfolio of small molecule antiviral therapeutics, including next-generation core inhibitor ABI-4334 for the treatment of HBV, long-acting helicase-primase inhibitor ABI-5366 for herpes simplex virus.
Lead Product(s): ABI-4334
Therapeutic Area: Infections and Infectious Diseases Product Name: ABI-4334
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $100.0 million Upfront Cash: $100.0 million
Deal Type: Partnership October 17, 2023
Details:
ABI-6250, an orally bioavailable small molecule entry inhibitor, is the first development candidate nominated by the company for the treatment of chronic hepatitis D virus (HDV) infection.
Lead Product(s): ABI-6250
Therapeutic Area: Infections and Infectious Diseases Product Name: ABI-6250
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
ABI-4334 is a investigational next-generation, highly potent hepatitis B virus (HBV) core inhibitor, which is currently being investegated in phase I for Hepatitis B.
Lead Product(s): ABI-4334
Therapeutic Area: Infections and Infectious Diseases Product Name: ABI-4334
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
ABI-5366 is a long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program. It has low clearance, will enhance both adherence and antiviral activity
Lead Product(s): ABI-5366
Therapeutic Area: Infections and Infectious Diseases Product Name: ABI-5366
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
The observed PK for the new tablet formulation of ABI-H3733 was consistent with predictions from preclinical studies, providing exposure equivalent to the liquid formulation evaluated in the Phase 1a study for 3733.
Lead Product(s): ABI-H3733
Therapeutic Area: Infections and Infectious Diseases Product Name: ABI-H3733
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
ABI-4334 is an investigational next-generation core inhibitor that is optimized for significantly increased potency against covalently closed circular DNA (cccDNA) formation and new virus production versus first-generation core inhibitors.
Lead Product(s): ABI-4334
Therapeutic Area: Infections and Infectious Diseases Product Name: ABI-4334
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
ABI-4334, novel hepatitis B core inhibitor, accelerates capsid assembly and inhibits cccDNA formation via multiple pathways, in preclinical data it demonstrate the core inhibitor activity of ABI-4334 against pgRNA encapsidation and covalently closed circular DNA formation.
Lead Product(s): ABI-4334
Therapeutic Area: Infections and Infectious Diseases Product Name: ABI-4334
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2022
Details:
AB-729 is a subcutaneously-delivered RNAi therapeutic specifically designed to reduce all HBV viral antigens, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to virus.
Lead Product(s): AB-729,Vebicorvir,Entecavir
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-729
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Arbutus Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus.
Lead Product(s): AB-729,Vebicorvir,Entecavir
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-729
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Arbutus Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
Preclinical data presented for ABI-H3733, with its best-in-class potential, demonstrates the candidate's potent activity against both cccDNA formation and pre-genomic RNA (pgRNA) encapsidation.
Lead Product(s): ABI-H3733
Therapeutic Area: Infections and Infectious Diseases Product Name: ABI-H3733
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
